skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines lecanemabQuestion & answer

lecanemab · Medicine question

What risk may increase when lecanemab is used with thrombolytic agents?

iatroX medicinesPublished 8 November 2026

The answer

Answer

The risk of intracerebral haemorrhage may increase when lecanemab is used with thrombolytic agents.

Sources for this answer

Leqembi 100 mg/mL concentrate for solution for infusionEisai Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 6Document updated 17 July 2026

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

More questions about lecanemab

Can lecanemab be used during pregnancy?Are there data on the effects of lecanemab on human fertility?How does lecanemab act on amyloid beta in the brain?How is Leqembi (lecanemab) concentrate for solution for infusion administered?How long must women of childbearing potential use effective contraception during and after lecanemab treatment?Is it known whether lecanemab passes into human breast milk?

lecanemab

Read the wider context, including uses, precautions and the sources behind this medicine guide.

Read the lecanemab guide

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX